# Azienda Usl di Bologna

Organization · id `cardio:org-azienda-usl-di-bologna` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ROR record 02mby1820](<https://ror.org/02mby1820>), retrieved 18 November 2026. No person wrote or checked this page.

## In plain language

An organization that ClinicalTrials.gov lists as a sponsor or collaborator of 3 trials in this atlas.

## Technical summary

Sponsor class other government. Matched to ROR record 02mby1820 by an exact name.

## The registry's words

- Sponsor name: Azienda Usl di Bologna
- Sponsor class: OTHER\_GOV
- ROR name: Azienda USL di Bologna

## Connected pages

- Sponsors: Fibrinogen Replacement to Prevent Intracranial Haemorrhage in Ischemic Stroke Patients After Thrombolysis (FibER) (`cardio:ct-nct05300672`)
- Sponsors: Percutaneous Stellate Ganglion Block as First Line Treatment in Patients With Electrical Storm: the STAR 2 Study (`cardio:ct-nct07841080`)
- Sponsors: Personalized Antiplatelet Therapy to Prevent Recurrent Cardiovascular Events in After Ischemic Stroke (`cardio:ct-nct07943026`)

## Provenance

Content hash: 089c9f45f127f019660b2ec14b26ebe2a941755a04d573413133c507563ef6d8
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
